People: Lorus Therapeutics Inc (LRUSF.PK)

LRUSF.PK on OTC Markets Group

0.44USD
31 Jul 2014
Price Change (% chg)

$-0.01 (-1.46%)
Prev Close
$0.44
Open
$0.44
Day's High
$0.44
Day's Low
$0.44
Volume
525
Avg. Vol
9,303
52-wk High
$0.93
52-wk Low
$0.17

Search Stocks

Summary

Name Age Since Current Position

William Rice

2013 Chairman of the Board, Chief Executive Officer

Gregory Chow

2013 Chief Financial Officer

Elizabeth Williams

2013 Finance Director, IR Contact Officer

Daniel Von Hoff

2013 Senior Vice President - Medical Affairs

Yoon Lee

2008 Vice President - Research

Jim Wright

2013 Lead Director

Denis Burger

69 2011 Independent Director

Brad Thompson

2013 Independent Director

Brian Underdown

72 2013 Independent Director

Mark Vincent

2007 Independent Director

Warren Whitehead

2011 Independent Director

Biographies

Name Description

William Rice

Dr. William G. Rice has been appointed as Chairman of the Board, Chief Executive Officer of Lorus Therapeutics Inc., with effect from October 28, 2013. Dr. Rice was most recently President, CEO and Chairman of the Board at Cylene Pharmaceuticals, Inc., a clinical-stage private company where he led the strategic and financing activities to design and develop small molecule therapeutics to exploit CK2-driven pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Prior to Cylene, Dr. Rice was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc., served as Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine.

Gregory Chow

Mr. Gregory K. Chow is Chief Financial Officer of Lorus Therapeutics Inc. Mr. Chow previously held the position of Managing Director, and led the Private Placements team in the Life Sciences Investment Banking Group at Wedbush Securities. Prior to joining Wedbush, he was a Director in the Private Placements / Equity Capital Markets Group at RBC Capital Markets where he led the life science private capital activities. Mr. Chow's transactional experience covers a broad range of equity and equity-linked financings that include Initial Public Offerings, Follow-Ons, Confidentially Marketed Public Offerings, Registered Directs, Private Investment in Public Equities (PIPEs) and private placements for private companies. Prior to RBC, he directed the Private Capital Group at Wells Fargo Securities, and was a Senior Auditor at BDO Seidman, LLP. Mr. Chow is a Certified Public Accountant (Inactive) in the State of California. Mr. Chow received his MBA in Finance from the Wharton School at the University of Pennsylvania, and his BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.

Elizabeth Williams

Ms. Elizabeth Williams is Finance Director of Lorus Therapeutics Inc. Prior to joining Lorus in July 2004, Ms. Williams was an Audit Manager with Ernst & Young LLP. Ms. Williams is a chartered accountant and has received a bachelor’s degree in business administration.

Daniel Von Hoff

Yoon Lee

Dr. Yoon Lee , PhD is Vice President - Research of Lorus Therapeutics Inc. Dr. Lee has been with Lorus for ten years, most recently serving as the Director of Research. He joined Lorus in 1999 through the merger with GeneSense Technologies Inc., where he was a Research Scientist integrally involved in the development of GeneSense oligonucleotide therapeutics program.

Jim Wright

Dr. Jim A. Wright, Ph.D., has been re-designated as Lead Director of Lorus Therapeutics Inc., with effect from October 28, 2013. Dr. Wright is presently Chief Executive Officer of NuQuest Bio Inc. since 2006 and until 2005 was Professor in the Faculties of Science and Medicine at the University of Manitoba. As of July 1, 2010, Dr. Wright accepted a position as an Adjunct Professor in the Department of Biochemistry and Biomedical sciences at McMaster University. Dr. Wright co-founded GeneSense Technologies Inc. in 1996, and served as Lorus' President, Chief Scientific Officer and a member of the Board of Directors in October 1999 on a merger with GeneSense. In September 2006, he stepped down as the President and Chief Executive Officer of Lorus.

Denis Burger

Dr. Denis R. Burger, Ph.D., is Independent Director of Lorus Therapeutics Inc. Dr. Burger is currently the executive Chairman of BioCurex, Inc. Dr. Burger was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, an Oregon based biotechnology company from 1992 to March 2007. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. Dr. Burger received his MSc and PhD in Microbiology and Immunology from the University of Arizona. Dr. Burger is also currently on the Board of Trinity Biotech plc. and BioCurex, Inc.Executive Chairman, BioCurex, Inc. (2009 to present) (biotechnology company).

Brad Thompson

Dr. Brad Thompson has been appointed as Independent Director of Lorus Therapeutics Inc., with effect from June 27, 2013. Dr. Thompson is an experienced and respected biotechnology professional who has held the positions of Chairman of the Board and President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. Prior to his role with Oncolytics Dr. Thompson was the Chief Executive Officer of Synsorb Biotech from 1994 to 1999. Dr. Thompson is also currently a board member of Immunovaccine Inc. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.

Brian Underdown

Dr.Brain J. Underdown is Independent Director of Lorus Therapeutics Inc.He is Managing Director, Lumira Capital (1997 to present) (life science venture capital investment manager).

Mark Vincent

Dr. Mark D. Vincent is Independent Director of Lorus Therapeutics Inc. Dr. Vincent is a Professor of Oncology at the University of Western Ontario and a staff medical oncologist at the London Regional Cancer Program. Dr. Vincent is also the co-founder and Chief Executive Officer of Sarissa, Inc. since 2000. Physician; medical oncologist, London Regional Cancer Program Cancer Care Ontario (1990 to present) (cancer care facility).

Warren Whitehead

Mr. Warren Whitehead is Independent Director of Lorus Therapeutics Inc. Mr. Whitehead is a Certified Management Accountant who has held senior financial management positions in several biotechnology and pharmaceutical companies. Most recently he served as Chief Financial Officer of ARIUS Research Inc., providing financial guidance and leadership during the acquisition of ARIUS by Roche in 2008. Prior to that Mr. Whitehead was CFO at Labopharm Inc., where he completed a series of public equity financings and a NASDAQ IPO. He is currently a member of the board of directors of PlantForm Corporation, a life sciences company that develops biosimilar antibody drugs for treatment of cancer and other critical illnesses.He is Chief Financial Officer, Amorfix Life Sciences (2013 to present) (biotechnology company).

Basic Compensation

Options Compensation

Search Stocks